MCID: HRN003
MIFTS: 40

Heroin Dependence malady

Categories: Mental diseases

Aliases & Classifications for Heroin Dependence

Aliases & Descriptions for Heroin Dependence:

Name: Heroin Dependence 12 42 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9976
MeSH 42 D006556
NCIt 47 C34694
UMLS 69 C0019337

Summaries for Heroin Dependence

Disease Ontology : 12 An opiate dependence that involves the continued use of heroin despite problems related to use of the substance.

MalaCards based summary : Heroin Dependence is related to personality disorder and intracranial cavernous angioma. An important gene associated with Heroin Dependence is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Peptide ligand-binding receptors and Amphetamine addiction. The drugs Cocaine and Heroin have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and pituitary, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Heroin Dependence

Diseases related to Heroin Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 59)
id Related Disease Score Top Affiliating Genes
1 personality disorder 29.7 DRD2 DRD4 OPRM1 PDYN SLC6A3
2 intracranial cavernous angioma 10.2 DRD2 SLC6A3
3 splenic abscess 10.2 DRD2 SLC6A3
4 sphenoorbital meningioma 10.2 DRD2 DRD4
5 scoliosis 10.2 DRD2 SLC6A3
6 peripheral vertigo 10.2 OPRD1 OPRM1
7 cervicitis 10.1 OPRD1 OPRM1
8 nephrogenic adenoma of the urethra 10.1 DRD2 SLC6A3
9 mastitis 10.1 DRD4 SLC6A3
10 c8 deficiency, type ii 10.1 DRD2 DRD4 OPRM1
11 hypocalcemia, autosomal dominant 2 10.1 PDYN SLC6A3
12 pyromania 10.1 DRD2 DRD4 SLC6A3
13 colorectal adenocarcinoma 10.1 DRD2 DRD4 SLC6A3
14 cytomegalic congenital adrenal hypoplasia 10.1 DRD2 DRD4
15 rectosigmoid junction neoplasm 10.1 DRD2 DRD4 SLC6A3
16 carotid stenosis 10.1 DRD2 DRD4 SLC6A3
17 autoimmune disease of endocrine system 10.1 OPRM1 PDYN
18 mucinous adenocarcinoma 10.1 DRD2 DRD4 SLC6A3
19 hepatitis d 10.1 DRD2 DRD4 SLC6A3
20 aortic valve disease 2 10.1 DRD2 DRD4 SLC6A3
21 chronic conjunctivitis 10.0 DRD2 DRD4 SLC6A3
22 usher syndrome 10.0 DRD2 SLC6A3
23 acute contagious conjunctivitis 10.0 DRD2 OPRM1 PDYN
24 apperceptive agnosia 10.0 ANKK1 DRD2
25 cervical carcinosarcoma 10.0 OPRM1 PDYN
26 ellis-van creveld syndrome 10.0 DRD2 DRD4 SLC6A3
27 brain glioblastoma multiforme 10.0 DRD2 GABRB2 SLC6A3
28 parotid gland cancer 9.9 DRD2 PDYN SLC6A3
29 antisocial personality disorder 9.9
30 strongyloidiasis 9.9 ANKK1 DRD2 SLC6A3
31 intracranial aneurysm 9.9 ANKK1 DRD2 DRD4
32 hepatitis 9.9
33 borderline personality disorder 9.9
34 alopecia 9.9 ANKK1 DRD2 DRD4
35 paraphilia disorder 9.9 AUTS2 DRD2 DRD4 SLC6A3
36 simultanagnosia 9.9 OPRM1 PDYN
37 transmitted_by 9.9 DRD2 OPRM1 PDYN SLC6A3
38 autism spectrum disorder 9.8 DRD4 OPRM1 PDYN SLC6A3
39 retinoblastoma 9.8 DRD2 DRD4 PDYN SLC6A3
40 basal cell carcinoma 3 9.8 ANKK1 DRD2 OPRM1 SLC6A3
41 cecal benign neoplasm 9.8 ANKK1 DRD2 DRD4 SLC6A3
42 hypereosinophilic syndrome 9.8 DRD2 DRD4 OPRD1 OPRM1 SLC6A3
43 schizophrenia 9.7
44 hepatitis c virus 9.7
45 hepatitis c 9.7
46 post-traumatic stress disorder 9.7
47 suppurative periapical periodontitis 9.6 AUTS2 DRD2 OPRD1 OPRM1 PDYN
48 neuronitis 9.6
49 substance dependence 9.6
50 cocaine dependence 9.6

Graphical network of the top 20 diseases related to Heroin Dependence:



Diseases related to Heroin Dependence

Symptoms & Phenotypes for Heroin Dependence

MGI Mouse Phenotypes related to Heroin Dependence:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.92 AUTS2 DRD2 DRD4 GABRB2 OPRD1 OPRM1
2 homeostasis/metabolism MP:0005376 9.8 OPRD1 OPRM1 PDYN SLC6A3 DRD2 DRD4
3 integument MP:0010771 9.55 DRD2 OPRD1 OPRM1 PDYN SLC6A3
4 nervous system MP:0003631 9.5 DRD2 DRD4 GABRB2 OPRD1 OPRM1 PDYN
5 no phenotypic analysis MP:0003012 9.02 AUTS2 DRD2 OPRD1 OPRM1 PDYN

Drugs & Therapeutics for Heroin Dependence

Drugs for Heroin Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 169)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 50-36-2 5760 446220
2
Heroin Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 561-27-3 5462328
3
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1 76-99-3 4095
4
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 16590-41-3 5360515
5
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 52485-79-7 40400 644073
6
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
7
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-61-6, 62-31-7 681
8
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
9
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 465-65-6 5284596
10
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
11 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 3,Phase 2,Phase 1
13 Narcotic Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
14 Narcotics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Anti-Anxiety Agents Phase 4,Phase 2
20 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
21 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Antitussive Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24
Serotonin Phase 4,Phase 3 50-67-9 5202
25 Serotonin Agents Phase 4,Phase 3
26 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
27 Anesthetics Phase 4,Phase 2,Phase 1
28 Anesthetics, Local Phase 4,Phase 2,Phase 1
29 Dopamine Agents Phase 4,Phase 2,Phase 3,Phase 1
30 Vasoconstrictor Agents Phase 4,Phase 2,Phase 1
31 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
32 Buprenorphine, Naloxone Drug Combination Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Oxytocics Phase 4
34
Morphine Approved, Investigational Phase 3,Phase 2,Phase 1 57-27-2 5288826
35
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
36
Clonidine Approved Phase 3,Phase 1 4205-90-7 2803
37
Memantine Approved, Investigational Phase 2, Phase 3 19982-08-2 4054
38
Amphetamine Approved, Illicit Phase 3,Phase 1 300-62-9 5826 3007
39
Hydromorphone Approved, Illicit Phase 3,Phase 2,Phase 1 466-99-9 5284570
40
Benzocaine Approved Phase 3,Phase 1 1994-09-7, 94-09-7 2337
41
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
42
Mianserin Approved Phase 3 24219-97-4 4184
43
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
44
Mirtazapine Approved Phase 3 85650-52-8, 61337-67-5 4205
45 tannic acid Approved, Nutraceutical Phase 3,Phase 1
46 Excitatory Amino Acid Antagonists Phase 3,Phase 2
47 Excitatory Amino Acids Phase 3,Phase 2
48 Autonomic Agents Phase 3,Phase 1,Phase 2
49 Antiparkinson Agents Phase 2, Phase 3
50
Ethylene Phase 3 74-85-1 6325

Interventional clinical trials:

(show top 50) (show all 148)
id Name Status NCT ID Phase
1 Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches Unknown status NCT00750217 Phase 4
2 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
3 A Stepwise Strategy Utilizing Buprenorphine and Methadone Completed NCT00310934 Phase 4
4 Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14 Completed NCT00015340 Phase 4
5 Effects of Buspirone in Opiate Withdrawal Completed NCT00326235 Phase 4
6 Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT Completed NCT01471145 Phase 4
7 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED) Completed NCT00604188 Phase 4
8 Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population Completed NCT02038790 Phase 4
9 Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry Recruiting NCT01999946 Phase 4
10 Buprenorphine to Improve HIV Care Engagement and Outcomes (BRAVO) Recruiting NCT01936857 Phase 4
11 Biomarkers of Injectable Extended Release Naltrexone Treatment Enrolling by invitation NCT02324725 Phase 4
12 Oxytocin and Cognitive Behavioral Therapy in Drug Dependence Terminated NCT00975416 Phase 4
13 Combined Therapy of Methadone and Dextromethrophan Unknown status NCT01189097 Phase 3
14 Comparing Acute and Continuous Drug Abuse Treatment: A Randomized Clinical Trial Unknown status NCT01003496 Phase 3
15 Memantine as a Supplement to Naltrexone in Treating Heroin Dependence Completed NCT00476242 Phase 2, Phase 3
16 Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone Completed NCT01760473 Phase 3
17 Behavioral Naltrexone Therapy (BNT) for Promoting Adherence to Oral Naltrexone (BNT-oral) vs Extended Release Injectable Depot Naltrexone (Depot-BNT); a Randomized Trial. A Free Treatment for Opiate Abuse. Completed NCT00577408 Phase 3
18 Study Comparing Liquid and Tablet Buprenorphine Formulations - 5 Completed NCT00000302 Phase 3
19 Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial Completed NCT00684554 Phase 2, Phase 3
20 Directly Administered HIV Therapy in Methadone Clinics Completed NCT00279110 Phase 2, Phase 3
21 Study to Assess Longer-term Opioid Medication Effectiveness (SALOME) Completed NCT01447212 Phase 3
22 Methadone Maintenance for Prisoners Completed NCT00378079 Phase 3
23 Buprenorphine for Prisoners Completed NCT00574067 Phase 3
24 Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1 Completed NCT00015171 Phase 3
25 Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1 Completed NCT00032968 Phase 3
26 Buprenorphine/Naloxone Versus Clonidine for Inpatient Opiate Detoxification - 1 Completed NCT00032955 Phase 3
27 Behavioral Drug and HIV Risk Reduction Counseling With MMT in China Completed NCT01389180 Phase 3
28 ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence Completed NCT00678418 Phase 3
29 The German Project of Heroin Assisted Treatment of Opiate Dependent Patients Completed NCT00268814 Phase 3
30 Reengineering Methadone Treatment Study of Patient-centered Methadone Treatment Completed NCT01442493 Phase 3
31 Prescription Opioid Addiction Treatment Study (POATS) Completed NCT00316277 Phase 3
32 Buprenorphine/Naloxone - Facilitated Rehabilitation for Opioid Dependent Adolescents - 1 Completed NCT00078130 Phase 3
33 Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence Completed NCT00630201 Phase 3
34 Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence Completed NCT00447564 Phase 3
35 A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction Completed NCT01114308 Phase 3
36 Re-Treatment Study of Probuphine in Opioid Addiction Completed NCT01262261 Phase 3
37 Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension) Completed NCT02537574 Phase 3
38 Mirtazapine as a Treatment for Co-Occurring Opioid and ATS Dependence in Malaysia Recruiting NCT02541526 Phase 3
39 An Open Label Study of Oral Minocycline for the Treatment of Patients With Co-occurring Opioid and ATS Dependence Recruiting NCT02541500 Phase 3
40 Change the Cycle: An RCT to Prevent Injection Initiation Recruiting NCT02774954 Phase 3
41 Addiction Treatment in Russia: Oral vs. Naltrexone Implant Active, not recruiting NCT00218426 Phase 2, Phase 3
42 An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and ATS Dependence Active, not recruiting NCT02541513 Phase 3
43 Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia Active, not recruiting NCT01389167 Phase 3
44 Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway Active, not recruiting NCT01717963 Phase 3
45 The Effectiveness of Deep Brain Stimulation for Opioid Relapse Prevention Not yet recruiting NCT02440152 Phase 2, Phase 3
46 Study of Probuphine in Patients With Opioid Dependence Terminated NCT00772785 Phase 3
47 A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence Terminated NCT00768482 Phase 3
48 Directly Administered Antiretroviral Therapy (DAART) Among HIV-1infected Injecting Drug Users (IDUs) in Chennai, India Withdrawn NCT00709007 Phase 2, Phase 3
49 The Safety of Using Buprenorphine With Naloxone in a Buccal Film to Initiate Treatment of Opioid Dependent Subjects Withdrawn NCT02516436 Phase 3
50 Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction Unknown status NCT00609089 Phase 1, Phase 2

Search NIH Clinical Center for Heroin Dependence

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: heroin dependence

Genetic Tests for Heroin Dependence

Anatomical Context for Heroin Dependence

MalaCards organs/tissues related to Heroin Dependence:

39
Testes, Brain, Pituitary

Publications for Heroin Dependence

Articles related to Heroin Dependence:

(show top 50) (show all 229)
id Title Authors Year
1
A novel inhibitor of endocannabinoid catabolic enzymes sheds light on behind the scene interplay between chronic pain, analgesic tolerance, and heroin dependence. ( 27890603 )
2017
2
Depression and severity of substance dependence among heroin dependent patients with ADHD symptoms. ( 27997065 )
2017
3
Association between serotonin transporter gene polymorphisms and heroin dependence: a meta-analytic study. ( 27942217 )
2016
4
Association between dopamine D2 receptor gene polymorphisms and the risk of heroin dependence. ( 27819741 )
2016
5
Brain-derived neurotrophic factor serum levels in heroin-dependent patients after 26weeks of withdrawal. ( 26774004 )
2016
6
Polymorphisms in the 5-hydroxytryptamine receptor 3B gene are associated with heroin dependence in the Chinese Han population. ( 27773795 )
2016
7
Genome-Wide Association of Heroin Dependence in Han Chinese. ( 27936112 )
2016
8
Genome-Wide Pharmacogenomic Study on Methadone Maintenance Treatment Identifies SNP rs17180299 and Multiple Haplotypes on CYP2B6, SPON1, and GSG1L Associated with Plasma Concentrations of Methadone R- and S-enantiomers in Heroin-Dependent Patients. ( 27010727 )
2016
9
Influence of Duration of Heroin Dependence on Humoral Immunologic Indicators. ( 27610581 )
2016
10
Variants of opioid system genes are associated with non-dependent opioid use and heroin dependence. ( 27664554 )
2016
11
Heroin craving and its correlations with clinical outcome indicators in people with heroin dependence receiving methadone maintenance treatment. ( 26773990 )
2016
12
GABRB2 Haplotype Association with Heroin Dependence in Chinese Population. ( 26561861 )
2015
13
Changes in neurocognition and adherence over six months in HIV-infected individuals with cocaine or heroin dependence. ( 25484035 )
2015
14
Predictors of non-use of illicit heroin in opioid injection maintenance treatment of long-term heroin dependence. ( 25452049 )
2015
15
Long-term mortality, remission, criminality and psychiatric comorbidity of heroin dependence: 11-year findings from the Australian Treatment Outcome Study. ( 25619110 )
2015
16
Association between variable number of tandem repeats (VNTR) polymorphism in the promoter region of monoamine oxidase A (MAOA) gene and susceptibility to heroin dependence. ( 26298506 )
2015
17
MalmAP Treatment Referral and Intervention Study (MATRIS)-effective referral from syringe exchange to treatment for heroin dependence: a pilot randomized controlled trial. ( 26613636 )
2015
18
Single-nucleotide polymorphisms in dopamine receptor D1 are associated with heroin dependence but not impulsive behavior. ( 25966176 )
2015
19
QTc Prolongation in Veterans With Heroin Dependence on Methadone Maintenance Treatment. ( 26097838 )
2015
20
Evidence for the contribution of genetic variations in regulator of G protein signaling 9 to the genetic susceptibility of heroin dependence. ( 25591550 )
2015
21
Serum brain-derived neurotrophic factor levels and psychotic symptoms in heroin dependence. ( 26343470 )
2015
22
The BDNF Val66Met polymorphism and plasma brain-derived neurotrophic factor levels in Han Chinese heroin-dependent patients. ( 25640280 )
2015
23
Acknowledging Heroin Dependence as a Preventable Pediatric Chronic Medical Condition. ( 26163081 )
2015
24
Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence. ( 25781230 )
2015
25
PTSD risk associated with a functional DRD2 polymorphism in heroin-dependent cases and controls is limited to amphetamine-dependent individuals. ( 23647975 )
2014
26
Association analysis of GABRB3 promoter variants with heroin dependence. ( 25025424 )
2014
27
Chronic heroin dependence leading to adrenal insufficiency. ( 25221675 )
2014
28
Gender sameness and difference in recovery from heroin dependence: A qualitative exploration. ( 24041800 )
2014
29
Comparative study of the perceived quality of life of patients in treatment for cocaine and heroin dependence in Spain: differences by gender and time in treatment. ( 24712297 )
2014
30
The Evidence for the Contribution of the Autism Susceptibility Candidate 2 (AUTS2) Gene in Heroin Dependence Susceptibility. ( 25398668 )
2014
31
Metabotropic glutamate receptor 3 is associated with heroin dependence but not depression or schizophrenia in a Chinese population. ( 24498053 )
2014
32
Prevalence of antisocial personality disorder among Chinese individuals receiving treatment for heroin dependence: a meta-analysis. ( 25477719 )
2014
33
[Association study of CNR1, GAD1 and BDNF polymorphisms with male heroin dependence in the Dai population in Yunnan]. ( 25252306 )
2014
34
Comparative gene expression profiling analysis of lymphoblastoid cells reveals neuron-specific enolase gene (ENO2) as a susceptibility gene of heroin dependence. ( 21995595 )
2014
35
Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trial. ( 24725468 )
2014
36
The effect of heroin dependence on resumption of heroin self-administration in rats. ( 24613630 )
2014
37
Excessive suicide mortality and risk factors for suicide among patients with heroin dependence. ( 25456334 )
2014
38
Gender differences in prevalence and correlates of antisocial personality disorder among heroin dependent users in compulsory isolation treatment in China. ( 24342175 )
2014
39
Association between VNTR polymorphism in promoter region of prodynorphin (PDYN) gene and heroin dependence. ( 25048760 )
2014
40
Factors associated with one year retention to methadone maintenance treatment program among patients with heroin dependence in China. ( 24565169 )
2014
41
DRD3 variation associates with early-onset heroin dependence, but not specific personality traits. ( 24398431 )
2014
42
Association of OPRD1 polymorphisms with heroin dependence in a large case-control series. ( 22500942 )
2014
43
BDNF Val(66)Met genotype is associated with drug-seeking phenotypes in heroin-dependent individuals: a pilot study. ( 22339949 )
2013
44
Effects of independent and substance-induced major depressive disorder on remission and relapse of alcohol, cocaine and heroin dependence. ( 22775406 )
2013
45
Pathways to heroin dependence: time to re-appraise self-medication. ( 23075121 )
2013
46
Genetic analysis of AUTS2 as a susceptibility gene of heroin dependence. ( 22995765 )
2013
47
Multivariate analysis of dopaminergic gene variants as risk factors of heroin dependence. ( 23840506 )
2013
48
Gender Differences Among Prisoners With Pre-Incarceration Heroin Dependence Participating in a Randomized Clinical Trial of Buprenorphine Treatment. ( 23997546 )
2013
49
Association of the GDNF gene with depression and heroin dependence, but not schizophrenia, in a Chinese population. ( 24022000 )
2013
50
A Population-based Association Study of Casein Kinase 1 Epsilon Loci with Heroin Dependence in Han Chinese. ( 24338102 )
2013

Variations for Heroin Dependence

Expression for Heroin Dependence

Search GEO for disease gene expression data for Heroin Dependence.

Pathways for Heroin Dependence

GO Terms for Heroin Dependence

Cellular components related to Heroin Dependence according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 9.58 OPRD1 OPRM1 SLC6A3
2 axon GO:0030424 9.54 DRD2 OPRM1 SLC6A3
3 membrane raft GO:0045121 9.43 OPRD1 OPRM1 SLC6A3
4 integral component of plasma membrane GO:0005887 9.43 DRD2 DRD4 GABRB2 OPRD1 OPRM1 SLC6A3
5 postsynapse GO:0098794 9.32 DRD4 OPRM1
6 dendrite membrane GO:0032590 9.16 OPRD1 OPRM1
7 axon terminus GO:0043679 8.8 DRD2 OPRD1 PDYN

Biological processes related to Heroin Dependence according to GeneCards Suite gene sharing:

(show all 33)
id Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.73 DRD2 OPRM1 SLC6A3
2 neuropeptide signaling pathway GO:0007218 9.69 OPRD1 OPRM1 PDYN
3 chemical synaptic transmission GO:0007268 9.67 GABRB2 OPRD1 OPRM1 PDYN
4 adult locomotory behavior GO:0008344 9.66 DRD4 OPRD1
5 sensory perception of pain GO:0019233 9.65 OPRD1 OPRM1
6 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway GO:0007193 9.65 OPRD1 OPRM1
7 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.65 OPRD1 OPRM1
8 response to nicotine GO:0035094 9.64 DRD2 SLC6A3
9 positive regulation of multicellular organism growth GO:0040018 9.64 DRD2 SLC6A3
10 response to morphine GO:0043278 9.63 DRD2 OPRM1
11 regulation of sensory perception of pain GO:0051930 9.63 OPRD1 OPRM1
12 eating behavior GO:0042755 9.62 OPRD1 OPRM1
13 response to amphetamine GO:0001975 9.62 DRD2 DRD4
14 arachidonic acid secretion GO:0050482 9.61 DRD2 DRD4
15 behavioral response to cocaine GO:0048148 9.61 DRD2 DRD4
16 locomotory behavior GO:0007626 9.61 DRD2 OPRM1 SLC6A3
17 dopamine receptor signaling pathway GO:0007212 9.6 DRD2 DRD4
18 response to iron ion GO:0010039 9.59 DRD2 SLC6A3
19 negative regulation of cAMP biosynthetic process GO:0030818 9.58 DRD4 OPRM1
20 sensory perception GO:0007600 9.58 OPRM1 PDYN
21 dopamine metabolic process GO:0042417 9.57 DRD2 DRD4
22 prepulse inhibition GO:0060134 9.55 DRD2 SLC6A3
23 negative regulation of protein secretion GO:0050709 9.54 DRD2 DRD4
24 negative regulation of voltage-gated calcium channel activity GO:1901386 9.52 DRD2 DRD4
25 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.49 DRD2 DRD4
26 regulation of dopamine metabolic process GO:0042053 9.48 DRD4 SLC6A3
27 adenohypophysis development GO:0021984 9.46 DRD2 SLC6A3
28 opioid receptor signaling pathway GO:0038003 9.4 OPRD1 OPRM1
29 response to cocaine GO:0042220 9.33 DRD2 OPRM1 SLC6A3
30 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.32 DRD2 DRD4
31 response to histamine GO:0034776 9.26 DRD2 DRD4
32 negative regulation of adenylate cyclase activity GO:0007194 9.13 DRD2 DRD4 OPRM1
33 behavioral response to ethanol GO:0048149 8.8 DRD2 DRD4 OPRM1

Molecular functions related to Heroin Dependence according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.73 DRD2 DRD4 OPRD1 OPRM1
2 signal transducer activity GO:0004871 9.67 DRD2 DRD4 OPRD1 OPRM1
3 neuropeptide binding GO:0042923 9.4 OPRD1 OPRM1
4 drug binding GO:0008144 9.33 DRD2 DRD4 SLC6A3
5 opioid receptor activity GO:0004985 9.32 OPRD1 OPRM1
6 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.26 DRD2 DRD4
7 dopamine neurotransmitter receptor activity GO:0004952 8.96 DRD2 DRD4
8 dopamine binding GO:0035240 8.8 DRD2 DRD4 SLC6A3

Sources for Heroin Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....